Learn from leading cardio-oncology experts how MyoStrain® may help to stratify cardiotoxicity risk, optimize cardiovascular therapy, prevent and manage cardiotoxicity, and guide long-term survivors’ follow-up.
Watch NowAbout half of US adults have some form of cardiovascular disease, yet, it is often not until symptoms of cardiac damage appear that a patient is diagnosed with heart failure. This is because today's diagnostic standard cannot directly quantify the asymptomatic effects of disease, drugs and treatment on the heart. MyoStrain provides a uniquely rapid and accurate assessment to help physicians quantify asymptomatic changes in heart function early, treat patients proactively and manage individualized cardiac care across large at-risk populations.
The unique and proprietary MyoStrain® test quantifies segmental intra-myocardial strain to directly quantifies changes in contraction across 48 segments. This provides physicians with the sensitivity and accuracy needed to detect the early progression of heart dysfunction and initiate early intervention. MyoStrain is FDA-cleared and CE-mark certified, providing novel cardiac information–as well as superior speed, ease and accuracy–to help inform clinical decisions and improve patient outcomes.
The MyoStrain report provides physicians and patients with a MyoHealth Score, a quantitative and holistic measure of patient heart health representing the total percentage of normally functioning myocardium.
Calculated by dividing the number of left-ventricular segments with normal function by the total number of left-ventricular segments, the MyoHealth score provides a baseline of patient heart health. Physicians are able to identify patients who are at risk of adverse cardiac events early and initiate proactive treatment intervention to mitigate cardiac damage and protect the heart long-term.
+ 10-minute exam time
+ Twelve-heartbeat MRI scan
+ Realtime strain encoding
+ Generates report immediately
+ Rapid exam times enables higher scan volumes and improved clinical efficiencies
+ Quantifies contractility across 48 segments of LV and RV
+ Provides longitudinal and circumferential strain, global strain, and other traditional metrics
+ Consistent results independent of user and scanner type
+ Helps physicians to detect at-risk cardiac patients before symptoms occur
+ Helps physicians optimize treatment by monitoring the individual effects over time
+ Helps physicians to reduce hospitalizations, medications and mortality
+ Simple and easy-to-understand heart health score
+ Safe and non-invasive procedure
+ No contrast agents, exposure to radiation, or breath hold required
A MyoHealth baseline provides a longitudinal perspective of the patient's heart health. Each score can be plotted along a progressive dysfunction curve and serves as a powerful clinical tool to help quantify how the patient's heart health changes over time. This may help to significantly improve patient outcomes, as physicians are able to focus on individualizing treatment to the patient based on their response to therapy and monitor the heart long-term.
Published in the Journal of the American college of cardiology, the diagram above demonstrates MyoStrain's ability to accurate detect, risk-stratify and classify asymptomatic heart failure patients, highlighting MyoHealth (% normal myocardium) as a far more sensitive cardiac risk marker compared to traditional standard of care metrics such as LVEF. The diagram further illustrates a proactive diagnostic window for physicians to manage preventative treatment before damage occurs.
Become certified and learn how to refer patients to receive MyoStrain, read MyoStrain reports and make informed clinical decisions to transform your cardiac practice
MyoStress™ provides a rapid, safe and "needle-free" 15-minute stress test to designed to help physicians detect myocardial ischemia
MyoStrain's unique and proprietary segmental strain analysis provides novel cardiac information about patient heart health
